Avamab Pharma develops gene therapy treatments for infectious diseases. The company uses a platform called AAV-mAb to create and release specific monoclonal antibodies. These antibodies can be used to treat active infections or prevent infections from occurring. The process involves releasing a viral vector that targets specific cells. Target cells